Conclusions: Preliminary data of this study suggest that CS alone or in combination with GS is able to decrease significantly synovitis as measured by US. The decrease in synovitis after SYSADOA treatment has been correlated with an improvement in knee pain. The decrease in synovitis elicited by SYSADOA treatment in this retrospective study is in accordance with former reduction of synovitis signs shown by CS in other studies and could contribute to explain its symptomatic and structure disease modifying effects.
Purpose: African Americans with osteoarthritis (OA) report greater pain and functional limitations than Caucasians, but the reasons for these racial disparities are not well understood. This study examined factors underlying racial differences in pain and function among patients with hip and/or knee osteoarthritis (OA), including psychological variables that have not previously been examined in this context. Methods: Participants were n=491 African Americans and Caucasians enrolled in a clinical trial of telephone-based OA selfmanagement. All measures were obtained at baseline. Pain and function were assessed using the Arthritis Impact Measurement Scales-2 (AIMS2) subscales. Potential explanatory variables included demographic factors (age, gender, marital status, education, income, working status, health literacy), health-related factors (body mass index, self-reported health, joint(s) with OA, duration of OA symptoms, pain medication use, current exercise), and psychological factors (arthritis self-efficacy, problem-and emotionfocused pain coping, AIMS2 affect subscale). The AIMS2 pain subscale was also included in models of AIMS2 function. Potential explanatory variables that were associated with both race and pain or function, and that reduced the association of race with pain or function by ≥10%, were included in the final multivariable linear regression models where racial differences in AIMS2 pain and function scores were examined. Results: In unadjusted linear regression models, African American race was associated with higher (worse) AIMS2 pain scores (unadjusted B = 0.65, p<0.01) and higher (worse) AIMS2 function scores (unadjusted B = 0.59, p<0.01). African American race was no longer significantly associated with AIMS2 pain scores in the final regression model (B = 0.03, p=0.874); variables significantly associated with worse AIMS2 pain scores in that model were: worse AIMS2 affect scores, greater emotion-focused coping, lower arthritis self-efficacy, and fair or poor self-reported health. African American race was also no longer significantly associated with AIMS2 function scores in the final regression model (B = 0.07, p=0.509). Variables significantly associated with worse AIMS2 function scores were the same as those described above for AIMS2 pain scores. In addition, worse AIMS2 pain scores were significantly associated with worse AIMS2 function scores. Conclusions: Factors explaining racial differences in pain and function were largely psychological, including AIMS2 affect (which comprises mood and level of tension), use of emotion-focused coping, and arthritis self-efficacy. Self-management and psychological/behavioral interventions can influence these factors, and greater dissemination of these programs among African Americans may be a key step toward reducing racial disparities in OA-related pain and function.
DIFFERENTIAL REGULATION OF THE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-5 AND MATRIX METALLOPROTEASE-13 GENES BY THE MICRORNAS MIR-140 AND MIR-27A IN HUMAN OSTEOARTHRITIC CHONDROCYTES
expression was determined upon treatment of OA chondrocytes with cytokines and growth factors. Results: IGFBP-5 was expressed in human chondrocytes with levels significantly (p<0.04) lower in OA. Computational algorithms identified miR-140 and miR-27a as possible regulators of MMP-13 and IGFBP-5 expression. Data showed that both miR-NAs were expressed in chondrocytes. There was a significant (p<0.01) reduction in miR-140 expression in OA, whereas miR-27a expression was only slightly decreased. Transfection with pre-miR-140 significantly (p<0.005) decreased IGFBP-5 expression at 24 hours, while pre-miR-27a did not affect either MMP-13 or IGFBP-5. Treatment with anti-miR-27a, but not with anti-miR-140, significantly increased the expression of both MMP-13 (p<0.05) and IGFBP-5 (p<0.01) after 72 hours incubation. These data indicate that IGFBP-5 is a direct target of miR-140, whereas miR- Results: Several components of the Wnt pathway showed altered expression between normal and OA tissue. Strikingly, the greatest and most significant change was in Dkk3 expression, with a 10-fold increase in OA cartilage (p=0.00011) and a 3.5-fold increase in OA synovium (p=0.007) when compared to respective control tissues. Dkk3 expression decreased during chondrogenic differentiation of ATDC5 cells and to be decreased following TGFβ treatment of SW1353 cells. Immunohistochemical analysis of specimens from individuals with anteromedial gonarthrosis (AMG, a subtype of knee OA), demonstrated Dkk3 protein in chondrocytes of the superficial zones of the cartilage, but not the deeper zones. Additionally there is an increase in Dkk3 expression in superficial zone chondrocytes in damaged when compared to undamaged cartilage from within the same knee. Using ELISA we have shown increased Dkk3 protein in the synovial fluid of individuals with tricompartmental OA (n=4) versus those with unicompartmental cartilage lesions (n=10) (182ng/ml v 116 ng/ml, p<0.01, a single non-OA control synovial fluid measured 43ng/ml. Conclusions: Dkk3 is a molecule with poorly ascribed function, especially within the musculoskeletal system. In contrast to other members of the Dkk family, Dkk3 does not act consistently as a Wnt antagonist. Literature on a number of tumour-derived cells shows that Dkk3 can potentially regulate Wnt, TGFβ, BMP, FGF and Activin signalling and cell proliferation and apoptosis. These cellular processes are highly relevant to OA. In this preliminary study we have shown that Dkk3 is overexpressed in OA cartilage and synovium. Interestingly, the increased expression of Dkk3 is also detected at the protein level in the synovial fluid; with increased Dkk3 present as disease severity increases. Furthermore Dkk3 protein in cartilage is detected more highly in damaged articular cartilage when compared to macroscopically normal cartilage. The decreased expression of Dkk3 during chondrogenesis is suggestive of a role of Dkk3 not only in articular cartilage maintenance but also in development. We have also seen decreased expression of Dkk3 in response to TGFβ treatment. Our current work aims to identify the function of Dkk3 in articular chondrocytes, the signaling pathways activated by Dkk3 and the mechanisms causing increased Dkk3 expression in OA. Dkk3 is an intriguing molecule in the Wnt signalling field since the evidence for its function as a Wnt antagonist is at best equivocal. Evidence for a role for Dkk3 in OA is compelling. Dissecting its function in cartilage and OA will both shed light on its overall molecular mechanism of action, enhance our knowledge of the pathogenesis of OA and also uncover potential new therapeutic targets for chondroprotection. Purpose: Traumatic joint injury in humans, irrespective of immediate surgical intervention, increases the risk for osteoarthritis (OA) development in later years. OA involves articular cartilage degradation, characterized by release of aggrecan and collagen fragments, and subsequent loss of tissue integrity and mechanical properties. The evolution of this disease state from joint injury is not clearly understood. Aggrecanases play a major role in cartilage degradation, and ARGS-aggrecan generated by direct cleavage of aggrecan core protein by aggrecanases is the most abundant aggrecan fragment in OA synovial fluid (SF). The current study measures the level of aggrecanase generated ARGS-aggrecan fragments in the SF of humans with joint injuries in comparison to OA patients, and in preclinical animal models of joint injury, in order to understand the evolution of disease from injury and to facilitate pharmacologic intervention. Methods: The ARGS-aggrecan ELISA used anti-aggrecan ab, AHP0022 (Invitrogen) for capture, and BC-3 (Abcam) for detection. Aggrecan purified from human cartilage and cleaved with ADAMTS4 served as standard, the range of detection was 10-500 ng aggrecan. SF from patients with anterior cruciate ligament rupture (ACL, 53), meniscus injury (69), OA (11), and knee-healthy reference subjects (8) from Lund University, Sweden were tested for ARGS-aggrecan at appropriate dilutions. Joint instability was induced in rats by medial meniscal surgery. SF lavage samples were collected at 4 days, and at 1, 2, 3, 5 and 8 weeks post surgery. ARGS-aggrecan levels were determined with contralateral knees as controls. Results: ARGS-aggrecan concentrations ranged from 2-590 μg/ml in human SF samples. ACL, meniscus injury and OA SF
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